

UNITED STATES PATENT AND TRADEMARK OFFICE

UNITED STATES DEPARTMENT OF COMMERCE United States Patent and Trademark Office Address: COMMISSIONER OF PATENTS AND TRADEMARKS P.O. Box 1450 Alexandria, Viginia 22313-1450

APPLICATION NO.	FILING DATE	FIRST NAMED INVENTOR	ATTORNEY DOCKET NO.	CONFIRMATION NO.
09/446,634	12/23/1999	HIROSHI HAGIYA	Q57282	2661
7:	590 05/21/2003			
SUGHRUE MION ZINN MACPEAK & SEAS 2100 PENNSYLVANIA AVENUE NW WASHINGTON, DC 20037			EXAMINER	
			YU, MISOOK	
			ART UNIT	PAPER NUMBER
			1642	10
			DATE MAILED: 05/21/2003	16

Please find below and/or attached an Office communication concerning this application or proceeding.

1					
• • •	Applicati n N .	Applicant(s)			
Office Action Comments	09/446,634	HAGIYA ET AL.			
Office Action Summary	Examiner	Art Unit			
	MISOOK YU, Ph.D.	1642			
The MAILING DATE f this communication appropried for Reply	ears on th cover sheet	with the correspondence address			
A SHORTENED STATUTORY PERIOD FOR REPLY THE MAILING DATE OF THIS COMMUNICATION. - Extensions of time may be available under the provisions of 37 CFR 1.13 after SIX (6) MONTHS from the mailing date of this communication. - If the period for reply specified above is less than thirty (30) days, a reply If NO period for reply is specified above, the maximum statutory period we Failure to reply within the set or extended period for reply will, by statute, - Any reply received by the Office later than three months after the mailing earned patent term adjustment. See 37 CFR 1.704(b).	6(a). In no event, however, may within the statutory minimum of ill apply and will expire SIX (6) No cause the application to become	a reply be timely filed thirty (30) days will be considered timely. ONTHS from the mailing date of this communication. ABANDONED (35 U.S.C. § 133).			
Status					
1) Responsive to communication(s) filed on 11 M					
, <u> </u>	s action is non-final.				
3) Since this application is in condition for allowa closed in accordance with the practice under EDisp sition of Claims					
4)⊠ Claim(s) 1-4 and 20 is/are pending in the application.					
4a) Of the above claim(s) is/are withdraw	n from consideration.				
5)⊠ Claim(s) <u>1-4</u> is/are allowed.					
6)⊠ Claim(s) <u>20</u> is/are rejected.					
7) Claim(s) is/are objected to.		•			
8) Claim(s) are subject to restriction and/or	election requirement.	·			
Application Papers		,			
9) The specification is objected to by the Examiner					
10) The drawing(s) filed on is/are: a) accep					
Applicant may not request that any objection to the		•			
11) The proposed drawing correction filed on		disapproved by the Examiner.			
If approved, corrected drawings are required in rep 12) The oath or declaration is objected to by the Exa	•				
Pri rity under 35 U.S.C. §§ 119 and 120					
	priority under 25 LLC (C 5 110(a) (d) ar (f)			
13) Acknowledgment is made of a claim for foreign priority under 35 U.S.C. § 119(a)-(d) or (f). a) All b) Some * c) None of:					
	have been received				
1. Certified copies of the priority documents have been received.					
 2. Certified copies of the priority documents have been received in Application No 3. Copies of the certified copies of the priority documents have been received in this National Stage 					
application from the International Bur * See the attached detailed Office action for a list of	eau (PCT Rule 17.2(a)).			
14) Acknowledgment is made of a claim for domestic	priority under 35 U.S.	C. § 119(e) (to a provisional application).			
 a) The translation of the foreign language pro- 15) Acknowledgment is made of a claim for domestic 					
Attachment(s)					
1) Notice of References Cited (PTO-892) 2) Notice of Draftsperson's Patent Drawing R view (PTO-948) 3) Information Disclosure Statement(s) (PTO-1449) Paper No(s)	5) Notice	ew Summary (PTO-413) Paper No(s) of Informal Patent Application (PTO-152)			
S. Patent and Trademark Office					

Application/Control Number: 09/446,634

Art Unit: 1642

DETAILED ACTION

Receipt of sequence listing/statement and amendment filed 0n 3-11-2003 is acknowledged.

Claims 1-4, and 20 and pending and examined on merits.

Specification

Objection of claim is withdrawn in view of the amendment.

Claim Rejections - 35 USC § 112

Rejection of claims under 35 U.S.C. 112, second paragraph, as being indefinite for failing to particularly point out and distinctly claim the subject matter which applicant regards as the invention is withdrawn in view of the amendment.

Claim 20 remain rejected for reason of record under 35 U.S.C. 112, first paragraph, as containing subject matter which was not described in the specification in such a way as to enable one skilled in the art to which it pertains, or with which it is most nearly connected, to make and/or use the invention.

This rejection is maintained because of the limitation "DNA molecule encoding an effector protein". The specification teaches only one DNA molecule encoding "effector protein" for the products of claims 1-4.

The following is the exact copy of the previous Office action dealt with this issue. The specification at page 27, Example 4 teaches how to make the plasmid DNA of instant claim 2. The plasmid constructs claimed in instant claims 1-4 does not encode fusion protein, but the DNA encoding "effector protein" recited in claim 20 encodes fusion protein of yeast Gal4 linked to human PPAR. The specification at Example 3 describes how to make the DNA construct, which encodes yeast Gal4- human PPAR fusion protein. Figures 1-4 of the instant application show that more of the two DNA transfected cells die, compared to control cells in presence of the PPAR activator compounds. The specification in the paragraph bridging pages 31 and 32 interpret the cell death caused by increased expression of Fas cytosolic domain. The synopsis of the event is that the Gal4 part of the fusion protein "the effector protein" binds to UAS

Application/Control Number: 09/446,634

Art Unit: 1642

site of the DNA construct of claim 2 when the PPAR part of the fusion protein is stimulated by the PPAR activator compounds used in Figs. 1-4, which in turn stimulates expression of Fas cytosolic domain under Gal4 enhancer element and this expression, i.e. Fas cytosolic domain causes cell death.

Reciting a specific nucleic acid molecule encoding the effector protein of Fig. 1-4 would obviate this rejection. See instant claim 1 for the claim construction for the nucleic acid molecule encoding *the* effector protein; specific SEQ ID describing the nucleic acid is not necessary because each component of the effector is well known in the art.

Allowable Subject Matter

Claims 1-4 are allowed.

Conclusion

THIS ACTION IS MADE FINAL. Applicant is reminded of the extension of time policy as set forth in 37 CFR 1.136(a).

A shortened statutory period for reply to this final action is set to expire THREE MONTHS from the mailing date of this action. In the event a first reply is filed within TWO MONTHS of the mailing date of this final action and the advisory action is not mailed until after the end of the THREE-MONTH shortened statutory period, then the shortened statutory period will expire on the date the advisory action is mailed, and any extension fee pursuant to 37 CFR 1.136(a) will be calculated from the mailing date of the advisory action. In no event, however, will the statutory period for reply expire later than SIX MONTHS from the mailing date of this final action.

Any inquiry concerning this communication or earlier communications from the examiner should be directed to MISOOK YU, Ph.D. whose telephone number is 703-308-2454. The examiner can normally be reached on 8 A.M. to 5:30 P.M., every other Friday off.

If attempts to reach the examiner by telephone are unsuccessful, the examiner's supervisor, Anthony C Caputa can be reached on 703-308-3995. The fax phone numbers for the organization where this application or proceeding is assigned are 703-

Application/Control Number: 09/446,634

Art Unit: 1642

305-3014 for regular communications and 703-872-9307 for After Final communications.

Any inquiry of a general nature or relating to the status of this application or proceeding should be directed to the receptionist whose telephone number is 703-308-0196.

Misook Yu, Ph.D. May 17, 2003

ANTHONY C. CAPUTA
SUPERVISORY PATENT EXAMINER
TECHNOLOGY CENTER 1600